Literature DB >> 6508270

Susceptibilities of 45 clinical isolates of Proteus penneri.

M Fuksa, S Krajden, A Lee.   

Abstract

Patterns of susceptibility of 45 Proteus penneri clinical isolates to 14 antimicrobial agents were evaluated by a macrobroth dilution method. All strains were highly susceptible to ceftizoxime, ceftazidime, moxalactam, cefoxitin, gentamicin, tobramycin, netilmicin, and, with few exceptions, to amikacin, piperacillin, and cefoperazone. Most strains were susceptible to cefotaxime and ceftriaxone. All strains were resistant to cefazolin and cefsulodin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508270      PMCID: PMC176184          DOI: 10.1128/AAC.26.3.419

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Laboratory evaluation of a rapid, automatic susceptibility testing system: report of a collaborative study.

Authors:  C Thornsberry; T L Gavan; J C Sherris; A Balows; J M Matsen; L D Sabath; F Schoenknecht; L D Thrupp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

2.  In vitro and in vivo antibacterial activity of T-1982, a new semisynthetic cephamycin antibiotic.

Authors:  M Tai; Y Fukuoka; A Yotsuji; K Kumano; M Takahata; H Mikami; T Yasuda; I Saikawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

3.  Antimicrobial and beta-lactamase inhibitory activities of carpetimycins A and B, new carbapenem antibiotics.

Authors:  F Kobayashi; Y Saino; T Koshi; Y Hattori; M Nakayama; A Iwasaki; T Mori; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

4.  Comparative activities of 13 beta-lactam antibiotics.

Authors:  H L Muytjens; J van der Ros-van de Repe
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

5.  Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.

Authors:  L W Ayers; R N Jones; A L Barry; C Thornsberry; P C Fuchs; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

6.  Antibacterial activities of SM-1652 compared with those of other broad-spectrum cephalosporins.

Authors:  M Kato; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

7.  In vitro activity of temocillin (BRL 17421), a novel beta-lactamase-stable penicillin.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

8.  Identification of Proteus penneri sp. nov., formerly known as Proteus vulgaris indole negative or as Proteus vulgaris biogroup 1.

Authors:  F W Hickman; A G Steigerwalt; J J Farmer; D J Brenner
Journal:  J Clin Microbiol       Date:  1982-06       Impact factor: 5.948

9.  Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

Authors:  R N Jones; P C Fuchs; H M Sommers; T L Gavan; A L Barry; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

10.  In vitro activity of azthreonam, a monobactam antibiotic.

Authors:  N V Jacobus; M C Ferreira; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

View more
  7 in total

Review 1.  Potential virulence factors of Proteus bacilli.

Authors:  A Rózalski; Z Sidorczyk; K Kotełko
Journal:  Microbiol Mol Biol Rev       Date:  1997-03       Impact factor: 11.056

2.  Analysis of antibiotic resistance determinants in Proteus penneri.

Authors:  S Lukomski; M Pytlos; L Serwecinska; Z Sidorczyk; A Jaworski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

Review 3.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

4.  Bacteremia and subcutaneous abscess caused by Proteus penneri in a neutropenic host.

Authors:  H D Engler; K Troy; E J Bottone
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

5.  Urease activity of Proteus penneri.

Authors:  H L Mobley; B D Jones; J L Penner
Journal:  J Clin Microbiol       Date:  1987-12       Impact factor: 5.948

Review 6.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

7.  Expanded clinical spectrum of infections caused by Proteus penneri.

Authors:  S Krajden; M Fuksa; C Petrea; L J Crisp; J L Penner
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.